Quality of life assessment and overall survival in patients with mulitple myeloma after Tandem Autologous Stem Cell Transplantation (ASCT)

Not Applicable

Completed

• Conditions: Multiple Myeloma; Cancer - Myeloma; Blood - Haematological diseases

• Registration Number: ACTRN12609000595213
• Lead Sponsor: Clifford Craig Medical Research Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-07-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

patients of either gender, 18 years and above who are able to give consent and have either: a confirmed diagnosis of multiple myeloma according to the World Health Organization (WHO) classification or patients who have been enrolled in our protocol with tandem stem cell transplantation

Exclusion Criteria

Patient with renal impairment defined by an estimated creatinine clearance below < 15 ml/min based on the Cockcroft-Gault formula. (Creatinine clearance = (140-age) x ideal body weight (IBW in Kg) (x 0.85 if female) / (Serum creatinine. x 0.815).
Advanced liver disease (Child C with encephalopathy, ascites and a significantly elevated bilirubin, or pre-treatment coagulopathy).
Patients with Eastern Cooperative Oncology Group (ECOG) status>2

Study & Design

• Study Type: Interventional
• Study Design: Not specified